Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00414622 · ClinicalTrials.gov registry record · Phase 2
GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease
A Phase 2 study, sponsored by CoMentis.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00414622: Completed Phase 2 study, sponsored by CoMentis.
NCT00414622 is a Phase 2 study that has completed, run by CoMentis. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00414622, a Phase 2 study, has completed, sponsored by CoMentis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
A Double Blind, Placebo-Controlled Randomized Study to Compare the Safety and Tolerability of GTS-21 (25 Mg TID, 50 Mg TID, 75 Mg TID and 150 Mg TID) When Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease
Interventions
- DRUG DMXB-A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2006-11 |
| Est. Completion | 2007-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00414622
The ClinicalTrials.gov registry entry for NCT00414622 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CoMentis, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DMXB-A is the first listed.
NCT00414622 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00414622 about?
NCT00414622 is a clinical study titled "GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease". A Double Blind, Placebo-Controlled Randomized Study to Compare the Safety and Tolerability of GTS-21 (25 Mg TID, 50 Mg TID, 75 Mg TID and 150 Mg TID) When Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease
What is the current status of trial NCT00414622?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2006-11. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00414622?
The interventions under investigation include: DMXB-A (DRUG).
Who is sponsoring clinical trial NCT00414622?
This trial is sponsored by CoMentis, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.